1. Home
  2. BCTX

as of 03-09-2026 10:30am EST

$3.91
+$0.08
+2.09%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Founded: 2014 Country:
Canada
Canada
Employees: N/A City: WEST VANCOUVER
Market Cap: 28.8M IPO Year: 2025
Target Price: $40.00 AVG Volume (30 days): 180.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.35 EPS Growth: -21344.83
52 Week Low/High: $0.61 - $14.68 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 380.95%
P/E Ratio: -0.88 Index: N/A
Free Cash Flow: -28627321.0 FCF Growth: N/A

Latest BriaCell Therapeutics Corp. News

BCTX Breaking Stock News: Dive into BCTX Ticker-Specific Updates for Smart Investing

All BCTX News

Share on Social Networks: